dissemination – Page 66 – Communicable Diseases Research

The Oxford Royal College of General Practitioners Clinical Informatics Digital Hub: Protocol to Develop Extended COVID-19 Surveillance and Trial Platforms

Protocol

Published on 2020-07-022022-10-31
Journal: JMIR Public Health and Surveillance [Category] COVID-19,

Global academic response to COVID ‐19: Cross‐sectional study

Original Article

Published on 2020-07-012022-10-29
Journal: Learned Publishing [Category] COVID-19,

[키워드] characterized coronavirus COVID COVID‐19 Data sharing dissemination early stage editorial eligible investigator investigators MERS Middle East MOST open‐access pandemic Research SARS‐CoV‐2 syndrome the disease to define Volume
[DOI] 10.1002/leap.1317 PMC 바로가기 [Article Type] Original Article

Response to Commentary on “The neuroinvasive potential of SARS-CoV-2 may play a role in the respiratory failure of COVID-19 patients”

Comment

Published on 2020-07-012023-07-13
Journal: Journal of medical virology [Category] SARS,

[키워드] Cell susceptibility coronavirus dissemination nervous system
[DOI] 10.1002/jmv.25824 PMC 바로가기 [Article Type] Comment

Impact of pantoprazole on absorption and disposition of hydroxychloroquine, a drug used in Corona Virus Disease-19 (Covid-19): A structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-292022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Absorption administration All participant anticipated Area assigned AUC C max center changes in clinical Concentration control group Corona Course COVID-19 CYP2D6 CYP3A4 dissemination dose drug drug-drug interaction element enrolment enzyme activity Enzymes EudraCT Germany HCQ Hydroxychloroquine Impact inhibitor investigator Microdosing Midazolam mononuclear cell not blinded number objective Open-label outcome P450 Pantoprazole parallel group participant Patient PBMC PBMCs performed Peripheral blood Phase I plasma PPI probe protocol randomisation list randomised randomised controlled trial Randomized receive recruitment Registered registry reported Sample size secondary single dose Standard status Study protocol target cell treated treatment group Trial trial protocol Two-arm university Volunteer website Whole blood Yohimbine
[DOI] 10.1186/s13063-020-04476-y PMC 바로가기 [Article Type] Letter

Triiodothyronine for the treatment of critically ill patients with COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial

COVID-19 감염이 있는 중환자 치료를 위한 Triiodothyronine: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-06-262022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] (therapeutic dose) 1:1 48 hour 48 hours Acute myocardial infarction addition Administered administration adopted allocation sequence Alpha Analysis blinded Blinding Caregivers clinical evidence collected comparator conserved copy Corticosteroid COVID-19 COVID-19 infected patient COVID-19 infection CRF criterion Critical Critical illness Critically ill Critically ill patient critically ill patients database defined detect Device diagnosed dissemination dosage dose double-blind drug Drug administration ECMO effective Efficacy and safety element enrolled Estimated EudraCT excluded extubation favorable effect female patient Final final analysis Follow-up followed by Germany Greece group hypoxia hypoxic condition hypoxic conditions ICU Identifier Ill illness immune system include increased mortality indicate information infusion initiation of treatment injection intensive care unit interim analysis investigator IWRS less Life expectancy maintenance dose MAPK mechanical respiratory mechanical ventilation multi-organ dysfunction number objective outcome participant Patient performed pharmacological treatment Placebo placebo controlled trial Pregnancy Primary outcome protocol Pulmonary infection randomisation randomised randomised controlled trial randomization Randomized recruited recruitment reveal Sample size Sepsis severe systemic disease signaling pathways solution Sponsor status study groups Study protocol subject Support systemic disease therapeutic therapeutic dose Thyroid thyroid hormone tissue trauma Treatment treatment allocation Trial Trial registration triiodothyronine unblinding university university hospital ventilatory support Version Viral viral infection Viral load website with COVID-19
[DOI] 10.1186/s13063-020-04474-0 PMC 바로가기 [Article Type] Letter

Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19

Immunology

Published on 2020-06-262022-11-01
Journal: Frontiers in Immunology [Category] COVID-19, MERS, SARS,

[키워드] ACE2 Activation acute lung injury acute phase response acute respiratory distress Adhesion Molecule alveolar macrophage ARDS Bisphosphonates Blood Bone marrow Cell Combination COVID-19 CSS cytokine Cytokine storm syndrome decrease develop dissemination Endothelium expression Factors fibrinogen IL-1β IL-6 immature Impact increase infiltration of neutrophil Inflammation Inflammatory inflammatory monocytes Intervention Kallikrein-kinin system knowledge lung lung epithelial cell Lung infection Lung injury Monocytes MOST patients Platelets pro-thrombotic proinflammatory cytokines reducing renin-angiotensin system response SARS-CoV-2 SARS-CoV2 SARS-CoV2 infection severe COVID-19 stimulate syndrome systemic systemic inflammation TNF VEGF
[DOI] 10.3389/fimmu.2020.01626 PMC 바로가기 [Article Type] Immunology

Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol

Letter

Published on 2020-06-262022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 24 hour Administered airway allocation concealment Alpha ambient analysed aneurysms Anticoagulant treatment anticoagulation antiplatelet Arm arterial assigned Atrial fibrillation bleeding bleeding event block size Blood BMI Body Breastfeeding breath calculated Cancer clinical clinically Coagulopathy Concomitant conjunctival Continuous contributed Control control group Controlled trial corpus COVID-19 COVID19 criteria Critical D-dimer D-dimer level Day death defined detect diagnostic discharged disease severity dissemination dosage dose effective Efficacy and safety element enoxaparin Epistaxis EudraCT event events expected fibrinogen level gingival bleeding group Haemoglobin haemoptysis health-care hematemesis hematoma hemodynamic heparin High dose high risk history hospital discharge Hospital stay hospitalized patient hypersensitivity Hypothesis IL-6 Impaired impairing improvement IMV In-hospital indication initiated Inpatient INR internal Intervention intervention group Intra-articular intramuscular invasive Invasive mechanical ventilation involved Italian Italy laboratory parameter LMWH low dose low-molecular weight heparin macroscopic Major major bleeding management Mechanical mechanical ventilation medical intervention Medicine Modena NIV Non-invasive number objective occur Occurrence open label ophthalmic oral anticoagulant outcome oxygen paO2/fiO2 parallel group participant pathology Patient performed Pharyngeal swab plasma Platelet Pneumonia positive pregnancy test Presence pressure Primary outcome prophylactic dose prosthetic protocol random randomisation randomised randomised controlled randomised controlled trial randomization Rate receiving recorded recruited Rectal Bleeding reduce reduction in Registered renal function reported required respiratory risk risk of death Sample size SARS-CoV-2 secondary secure Severe COVID-19 pneumonia severe disease significantly Spontaneous standard oxygen therapy Stata status stratified stroke study drug Study protocol subcutaneously surgical susceptible symptomatic syndrome therapeutic dose therapy thrombocytopenia time transfusion Treatment unfractionated heparin unit Vascular venipuncture Venous Thromboembolism web-based system website weight Withdrawal worsening
[DOI] 10.1186/s13063-020-04475-z PMC 바로가기 [Article Type] Letter

Effect of hydroxychloroquine on COVID-19 prevention in cancer patients undergoing treatment: a structured summary of a study protocol for a randomised controlled trial

Letter

Published on 2020-06-262022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] 1:1 Acute Lymphoid Leukemia acute myeloid leukemia age anticipated approval approved assigned blinded blocks Breast cancer calculated Cancer cancer patient cardiac disease chemotherapeutic agent chronic pulmonary disease clinical Colon cancer company Computed tomography control group cough COVID-19 COVID-19 symptom curative intent data analyst disease dissemination Effect element examined exclusion criteria Fever FIVE follow-up period High-resolution Hydroxychloroquine IgG antibody incidence of COVID-19 include Intervention investigated Iran leukemia Lungs lymphoid lymphoma Mashhad Medical Sciences novel nucleic acid amplification number objective occur outcome parallel-group participant Patient patients performed pharmaceutical Placebo primary end point produced Prophylaxis protocol randomised randomised controlled trial randomization sequence Randomly randomly permuted blocks recruitment Registered registration date registry respiratory tract infection Sample size sensitivity Shortness of breath specific IgM status Study protocol Symptom Tablet the patient the SARS-CoV-2 virus total sample size treated Treatment Trial triple-blind two group Two-arm university website
[DOI] 10.1186/s13063-020-04485-x PMC 바로가기 [Article Type] Letter

A prospective, randomized, controlled study assessing vagus nerve stimulation using the gammaCore®-Sapphire device for patients with moderate to severe CoViD-19 Respiratory Symptoms (SAVIOR): A structured summary of a study protocol for a randomised controlled trial”

Letter

Published on 2020-06-262022-10-29
Journal: Trials [Category] Coronavirus, SARS,

[키워드] 1:1 Acute respiratory failure Administered Admission Adverse age Aneurysm Antibiotics atherosclerotic baseline blind blood pressure Brain cardiovascular disease carotid cerebrovascular accident cervical spine chronic clinical trial Complete congestive heart failure Consent control group Controlled trial Coronary artery disease cough COVID-19 criteria current cytokine Cytokine storm Day decrease Delay Disabled disease dissemination distress dose electrical element eligible enrolled evaluate expected Follow-up Gender growth Healthcare provider hemorrhage history hospital hospital discharge ICU admission Informed Initiation interleukin interleukin 6 Intervention less mechanical ventilation mechanical ventilator Mild moderate Mortality Myocardial infarction nerve stimulation number O2 Saturation objective occur Older open label outcome oxygen Oxygen level Oxygen therapy parallel group participant Patient patients with moderate per day persist positive prophylactically protocol pulmonary randomisation randomised randomised controlled randomised controlled trial randomization Randomized recruited recruitment reduce reduction regimen Registered required Research respiratory Respiratory failure Sample size Sapphire saturation second dose secondary severity Shortness of breath SOC Spain Standard Standard of care status storm stratified study group Study protocol subject supplemental oxygen supplemental oxygen requirement tested trauma Treatment tumor necrosis factor tumors uncontrolled Vague neurostimulation Valencia Ventilation ventilatory support website women
[DOI] 10.1186/s13063-020-04486-w PMC 바로가기 [Article Type] Letter

CytoResc – “CytoSorb” Rescue for critically ill patients undergoing the COVID-19 Cytokine Storm: A structured summary of a study protocol for a randomized controlled trial

CytoResc – COVID-19 사이토카인 폭풍을 겪고 있는 중환자를 위한 "CytoSorb" 구조: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-06-262022-08-13
Journal: Trials [Category] SARS, 임상,

[키워드] 1:1 24 hour 24 hours Acute kidney injury Acute respiratory failure Administered Analysis Antibiotics arterial arterial pressure Bacterial Berlin blinded Blinding block blocks Blood C-reactive protein C-reactive protein (CRP catecholamine cause center Chain Reaction Charité clinical Clinical course Clinical practice clinical trials clinically clinician comparator concentrations condition conducted contraindication COVID-19 COVID-19 patient COVID-19 patients Critical care Critically ill critically ill COVID-19 patients Critically ill patient critically ill patients cytokine Cytokine storm Cytokines Cytosorb CytoSorb® data set death defined dissemination dose element elevated Endpoint extracorporeal cytokine elimination feasibility Filter Formal Germany Hemodynamics hospital discharge Hospitalization hospitalized patient hospitalized patients hyperinflammation Hyperinflammatory ICU-treatment ICUs IIb IL-6 IMPROVE Inc. Inclusion inclusion criteria indication intensive care unit intensive care units interleukin interleukin-6 intervention effect mean arterial pressure mechanical ventilation molecular weight Mortality multicenter New Norepinephrine number objective observational study occur Open-label other conditions outcome parallel group participant Patient patients PCR PCT performed phase pilot study polymerase chain polymerase chain reaction polystyrene positive pressure Prevent primary endpoint procalcitonin Proinflammatory cytokine proinflammatory cytokines protocol randomization Randomized Randomized controlled trial reason for receive recruited reducing Registered registry renal replacement therapy replacement therapy rescue Respiratory failure Safety Safety assessment Sample size SARS-CoV-2 secondary Secondary outcomes Shock shown Standard of care statistician status stratified Study design Study protocol Suspected therapy toxin Treatment Trial Trial registration USA vasoplegic shock Vasopressor vasopressors website
[DOI] 10.1186/s13063-020-04501-0 PMC 바로가기 [Article Type] Letter